These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38643811)

  • 1. Prolonged delivery of HIV-1 vaccine nanoparticles from hydrogels.
    Mietzner R; Barbey C; Lehr H; Ziegler CE; Peterhoff D; Wagner R; Goepferich A; Breunig M
    Int J Pharm; 2024 May; 657():124131. PubMed ID: 38643811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presentation of HIV-1 Envelope Trimers on the Surface of Silica Nanoparticles.
    Thalhauser S; Peterhoff D; Wagner R; Breunig M
    J Pharm Sci; 2020 Jan; 109(1):911-921. PubMed ID: 31682830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
    Leaman DP; Lee JH; Ward AB; Zwick MB
    J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms.
    Brouwer PJM; Sanders RW
    Curr Opin HIV AIDS; 2019 Jul; 14(4):302-308. PubMed ID: 30994503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.
    Torrents de la Peña A; de Taeye SW; Sliepen K; LaBranche CC; Burger JA; Schermer EE; Montefiori DC; Moore JP; Klasse PJ; Sanders RW
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29367243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.
    Schiffner T; Pallesen J; Russell RA; Dodd J; de Val N; LaBranche CC; Montefiori D; Tomaras GD; Shen X; Harris SL; Moghaddam AE; Kalyuzhniy O; Sanders RW; McCoy LE; Moore JP; Ward AB; Sattentau QJ
    PLoS Pathog; 2018 May; 14(5):e1006986. PubMed ID: 29746590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
    Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.
    Pugach P; Ozorowski G; Cupo A; Ringe R; Yasmeen A; de Val N; Derking R; Kim HJ; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; Julien JP; Burton DR; Wilson IA; Sanders RW; Klasse PJ; Ward AB; Moore JP
    J Virol; 2015 Mar; 89(6):3380-95. PubMed ID: 25589637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-arm PEG/silica hydrogel for sustained ocular drug delivery.
    Lu C; Zahedi P; Forman A; Allen C
    J Pharm Sci; 2014 Jan; 103(1):216-26. PubMed ID: 24285503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers
    Ozorowski G; Cupo A; Golabek M; LoPiccolo M; Ketas TA; Cavallary M; Cottrell CA; Klasse PJ; Ward AB; Moore JP
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
    Ching L; Stamatatos L
    J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.